Drug Trial Radar · NCT07087912
Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases
Last checked: Nov 20, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
477
Planned (sponsor's estimate)
Start
Mar 16, 2026
Primary completion
Dec 30, 2027
Study completion Dec 30, 2028
Sponsor
- Lead sponsor
- University of Sao Paulo General HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Butantan Institute
- First posted
- Jul 28, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years, up to 59 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate whether the live attenuated tetravalent Butantan-Dengue vaccine (Butantan-DV) is safe and capable of inducing an immune response in patients aged 12 to 59 years with autoimmune rheumatic diseases (ARDs) who are clinically stable and under low-grade or no immunosuppression, as well as in healthy volunteers matched by sex and age. The main questions it aims to answer are: Does the vaccine induce adequate seroconversion in patients with ARDs compared to healthy controls? What is the frequency and intensity of common adverse events after vaccination in ARDs patients? Does physical activity levels and nutritional status influence vaccine-induced immune response in patients with ARDs? Researchers will compare patients with ARDs to healthy controls to evaluate if the vaccine elicits similar immune responses and safety profiles. All participants will: * receive a single 0.5 mL dose of the Butantan-DV vaccine via subcutaneous injection; * undergo blood sample collection before and after vaccination (baseline, Day 42, and Day 400) to assess antibody and cellular responses; * attend follow-up visits on Days 7, 14, and 42 for safety monitoring and laboratory tests; * report any symptoms or adverse events using a standardized diary for 42 days; * be followed for up to one year for long-term safety and immunogenicity assessments. * wear a device for 14 consecutive days to assess current and habitual physical activity levels. * answer three non-consecutive 24-hour dietary recalls, including at least one weekend day to assess nutritional status. * collect blood samples one-year after vaccination to access immunogenicity and cellular response. Researcher will also perform subgroups analysis in: A viremia subgroup (50 patients and 50 healthy controls) will provide additional samples on Days 1, 7, 14, 28, 42, and-if viremia is detected-Day 68, to evaluate post-vaccination viremia and its duration. An immunogenicity subgroup (\~20% of participants, n=96) will undergo cellular immune response testing via flow cytometry to evaluate T-cell responses.
Conditions
- Rheumatoid Arthritis (RA)
- Juvenile Idiopathic Arthritis (JIA)
- Systemic Lupus Erythematosus (SLE)
- Juvenile Systemic Lupus Erythematosus
- Systemic Sclerosis (SSc)
- Idiopathic Inflammatory Myopathies (IIMs)
- Axial Spondyloarthritis
- Psoriatic Arthritis (PsA)
- Granulomatosis With Polyangiitis
- Microscopic Polyangiitis
- Antiphospholipid Syndrome
- Takayasu Arteritis
Interventions
Dengue 1,2,3,4 (attenuated) vaccineBiological
A single 0.5 mL dose of the live attenuated tetravalent dengue vaccine (Butantan-DV), administered subcutaneously on Day 1. The vaccine contains attenuated viral strains for DENV-1, DENV-3, DENV-4, and a chimeric DENV-2 component. It is manufactured and formulated by the Instituto Butantan (São Paulo, Brazil).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Seroconversion Rate After VaccinationTime frame: From enrollment to day 42 after vaccination
- Frequency and Intensity of Common Adverse EventsTime frame: Baseline through Day 42.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Hospital das Clínicas da Faculdade de Medicina da USP
São Paulo, São Paulo, Brazil · Recruiting
Rheumatology Division, Faculdade de Medicina da USP
São Paulo, São Paulo, Brazil · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.